How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

366 results for

Intraocular Carbonic Anhydrase Inhibitor

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

Substances Growth Inhibitors Ophthalmic Solutions Pharmaceutical Solutions Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) domain optical coherence tomography [ Time Frame: 18 weeks ] Change in mean maximum PED height on spectral domain optical coherence tomography from baseline to final visit. Visual acuity [ Time Frame: 18 weeks ] Change in mean best available visual acuity from baseline to final visit. Mean intraocular pressure (IOP) [ Time Frame: 18 weeks ] Change in mean IOP from baseline to final visit. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study

2017 Clinical Trials

62. Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

of investigational product; or pilocarpine or carbonic anhydrase inhibitors within 7 days before the first dose of investigational product. Participant has a history of angle closure, ocular surgery, microinvasive glaucoma surgery device insertion, or laser surgery, except for the following procedures, which are allowed: uncomplicated cataract surgery, laser peripheral iridotomy with resultant angle of Shaffer grade 3 or 4, and postcataract neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser posterior (...) Antibodies, Drop Comfort Assessment and Ophthalmologic Examinations Reported as AEs [ Time Frame: From start of study drug administration to 9 days after last study drug administration ] The number of participants with clinically significant abnormalities in vital sign measurements, electrocardiogram (ECG), clinical laboratory assays, antidrug antibodies, drop comfort assessment, and ophthalmologic examinations reported as AEs will be reported. Secondary Outcome Measures : Change in Intraocular Pressure

2017 Clinical Trials

63. Additive Effect of Twice-daily Brinzolamide 1% / Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Government. Read our for details. ClinicalTrials.gov Identifier: NCT03150160 Recruitment Status : Completed First Posted : May 12, 2017 Results First Posted : February 25, 2019 Last Update Posted : February 25, 2019 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: The purpose of this study was to determine the incremental intraocular pressure (IOP) lowering that is achieved when

2017 Clinical Trials

64. Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy

Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Ophthalmic Solutions Pharmaceutical Solutions Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) 20, 2017 Last Update Posted : July 11, 2017 Sponsor: University Hospital of Patras Information provided by (Responsible Party): Constantinos D. Georgakopoulos, MD, PhD, University Hospital of Patras Study Details Study Description Go to Brief Summary: To compare the efficacy of a Brinzolamide/Brimonidine fixed combination (FC) with Brimonidine 0.2% in preventing intraocular pressure (IOP) elevations after neodymium: yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulotomy. Condition

2017 Clinical Trials

65. PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

(e.g. degenerations, diabetic retinopathy, retinal detachment) Ability Visual 20/200 or worse in any of the eyes. Subject with only one eye Eye diseases that contraindicate the use of Beta-blocker (BB) Alpha-adrenergic agonist (AA) or Carbonic anhydrase inhibitors (CAIs) Intraocular surgery less or equal to 6 months prior to the study Laser intraocular surgery less or equal to 3 months prior to the study Any abnormality preventing reliable applanation tonometry Unstable or uncontrolled (...) Ocular Hypertension Eye Diseases Pharmaceutical Solutions Ophthalmic Solutions Timolol Brimonidine Tartrate Dorzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme Inhibitors

2017 Clinical Trials

66. Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) period. Washout period: 20 hours. Patients in the period 2: the pharmacological intervention change to the opposite therapy for 30 days Condition or disease Intervention/treatment Phase Primary Open Angle Glaucoma Ocular Hypertension Drug: PRO-122 Drug: Krytantek Ofteno® Phase 3 Detailed Description: The American Academy of Ophthalmology Glaucoma Panel: The primary open angle glaucoma (POAG) is a progressive, chronic optic neuropathy in adults in which intraocular pressure (IOP) and other currently

2017 Clinical Trials

67. Glaucoma

. Pharmacological treatments which reduce the intraocular pressure include ocular beta-adrenoceptor blocking drugs, prostaglandin analogues, miotics, sympathomimetics, and ocular and systemic carbonic anhydrase inhibitors. There are little or no data on pregnancy outcomes following the use of these medications in pregnancy and an evidence-based assessment of risk to the developing fetus with maternal exposure is therefore not possible. However, untreated or under-treated glaucoma could potentially lead

2014 UK Teratology Information Service

68. Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma

Timolol Latanoprost Dorzolamide Ophthalmic Solutions Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Pharmaceutical Solutions Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2010 Clinical Trials

69. Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy

Perforations Retinal Diseases Eye Diseases Timolol Dorzolamide Ophthalmic Solutions Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Pharmaceutical Solutions Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2010 Clinical Trials

70. Acetazolamide

occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) Definition (CSP) carbonic anhydrase inhibitor that is sometimes effective against (...) From Related Chapters II. Mechanism Carbonic Anhydrase Inhibitor III. Indications treatment and prevention IV. Contraindications V. Dosing Prevention: 125 mg PO bid Start 24 hours before ascent Continue for 72 hours or until acclimitization to highest sleeping altitude at altitude: 125 mg PO qhs Treatment: 250 mg orally twice daily (up to 400 mg twice daily has been sed) Dose range: 125-250 mg PO qd-tid VI. Adverse Effects Peripheral s (common) Images: Related links to external sites (from Bing

2018 FP Notebook

71. Brinzolamide and timolol maleate suspension - Glaucoma and Ocular hypertension

in a similar manner to other carbonic anhydrase inhibitor/beta blocker combination products. Reasons for the Recommendation: 1. In the Common Drug Review (CDR) systematic review that included two double-blind randomized controlled trials, the reduction in intraocular pressure at six months was greater for Azarga compared with either individual component given alone, and was similar for Azarga compared with the combination product of dorzolamide 2% / timolol 0.5% (Cosopt). 2. Azarga costs less than either (...) individual component given alone and costs less than Cosopt. Of Note: The Committee noted that while Azarga costs less than other carbonic anhydrase inhibitor/beta blocker ophthalmic combination products, it costs more than prostaglandin analogue/beta blocker combination products. Background: Azarga is a combination of timolol, a beta-blocker, and brinzolamide, a carbonic anhydrase inhibitor. It has a Health Canada indication for the reduction of intraocular pressure (IOP) in patients with open-angle

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

72. Assessment of Depression, Anxiety, and Quality of Life in Singaporean Patients With Glaucoma. (Abstract)

for anxiety included: lower MD in the worse eye (P=0.004) and lower mean VFQ25 score (P=0.004). There was also no significant association between the use of topical β-blockers/carbonic anhydrase inhibitors with depression (P=0.793) or anxiety (P=0.282).There is a relatively high prevalence of depression (30%) and anxiety disorders (64%) among glaucoma patients in Singapore. Female glaucoma patients are more likely to suffer from depression. Other risk factors for depression include higher cup-disc ratio (...) . Patients with other types of glaucoma, and coexisting ocular or psychiatric disorders were excluded.Ophthalmic examination was carried out on all participants, which included best-corrected visual acuity (BCVA), intraocular pressure (IOP), gonioscopy, standard automated perimetry, and optic disc evaluation. Sociodemographic information and treatment histories were also collected.The Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), and Visual Function Questionnaire (VFQ25

2016 Journal of Glaucoma

73. Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

relevant MeSH terms: Layout table for MeSH terms Glaucoma, Open-Angle Ocular Hypertension Glaucoma Eye Diseases Timolol Brimonidine Tartrate Travoprost Brinzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme (...) Research Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension. Condition or disease Intervention/treatment Phase Open-angle Glaucoma Ocular Hypertension Drug: Brinzolamide 1%/Brimonidine 0.2% suspension Drug: Brinzolamide

2016 Clinical Trials

74. Effect of Acetazolamide on Optic Nerve Sheath Diameter in Laparoscopic Donor Nephrectomies

Last Update Posted: December 29, 2016 Last Verified: December 2016 Keywords provided by Dr. Ashish Singh Aditya, Postgraduate Institute of Medical Education and Research: optic nerve sheath diameter acetazolamide Additional relevant MeSH terms: Layout table for MeSH terms Intracranial Hypertension Brain Diseases Central Nervous System Diseases Nervous System Diseases Acetazolamide Anticonvulsants Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action (...) for Heart rate, Blood Pressure, pulse oximetry(Spo2), End Tidal Carbon Dioxide(ETCO2), Train Of Four(TOF) and Bi spectral index(BIS). Post operatively donors were reversed with injection neostigmine and glycopyrrolate. once return of spontaneous ventilation was well established and patient becomes conscious oriented trachea was extubated and donors were shifted to post anaesthetic care unit(PACU). Postoperatively donors were monitored for Heart rate, Blood Pressure, Spo2, Comfort Score, Visual analog

2016 Clinical Trials

75. Pressure Difference Between Brain and Eye: a Possible Cause to Normal Tension Glaucoma.

: Subject has normal tension glaucoma in one or both eyes (glaucomatous optic nerve head and corresponding visual field defects) Intraocular pressures before treatment did not exceed 21 mmHg. Occasional measurement up to 24 is accepted. Exclusion Criteria: History of brain disease or brain surgery History of other neurologic or ocular disease causing visual field loss Use of anticoagulants other than acetylsalicylic acid Use of carbonic anhydrase inhibitors Previous lumbar puncture Claustrophobia (...) Description: The trans-lamina cribrosa pressure difference (TLCPD), i.e. the difference between the intraocular pressure (IOP) and the intracranial pressure (ICP) has been suggested as a pathophysiological component in glaucoma. The theory is that high TLCPD, either due to elevated IOP or reduced ICP, can cause glaucomatous damage. Normal tension glaucoma (NTG) patients has been found to have a slightly reduced ICP when measured in horizontal position. However, in a previous study in healthy adult

2016 Clinical Trials

76. 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

-Arrhythmia Agents Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Concomitant therapy with preservative-free talfuprost drops administered once in the evening and dorzolamide/timolol fixed combination drops given twice daily. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy. Drug: tafluprost and dorzolamide/timolol Other Name: Saflutan, Taflotan, Cosopt PF Outcome Measures Go to Primary Outcome Measures : Mean 24-hour efficacy (average intraocular pressure readings over 24 hours) [ Time Frame: 3 months ] Secondary Outcome Measures

2016 Clinical Trials

77. The in Vivo Effect of Medical and Surgical Glaucoma Treatments on the Schlemm's Canal Micro-structure

and after cataract surgery Before and after vitrectomy surgery Before and after XEN™ Gel Stent implant The pharmacological branch- Before and during the treatment with prostaglandins analogs Before and during the treatment with alpha blockers Before and during the treatment with beta blockers Before and during the treatment with carbonic anhydrase inhibitor The laser branch- Before and after trabeculoplasty Before and after laser iridotomy Before and after yag capsulotomy laser Condition or disease (...) Before and after XEN™ Gel Stent implant pharmacological branch- Before and during the treatment with prostaglandins analogs Before and during the treatment with alpha blockers Before and during the treatment with beta blockers Before and during the treatment with carbonic anhydrase inhibitor laser branch- Before and after trabeculoplasty Before and after laser iridotomy Before and after yag capsulotomy laser Device: Optical coherence tomography imaging Outcome Measures Go to Primary Outcome Measures

2016 Clinical Trials

78. SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Tartrate Latanoprost Brinzolamide Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) Information provided by (Responsible Party): Alcon Research Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with open-angle glaucoma or ocular hypertension. Condition or disease Intervention/treatment Phase Open-Angle Glaucoma Ocular Hypertension Drug: Brinzolamide 1%/brimonidine 0.2

2015 Clinical Trials

79. Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

to baseline of any ocular hypotensive medication. In order to minimize potential risk to subjects due to IOP elevations during the washout period, investigator may choose to substitute a parasympathomimetic or carbonic anhydrase inhibitor in place of a sympathomimetic, alpha-agonist, beta-adrenergic blocking agent, or prostaglandins. However, subjects must have discontinued all ocular hypotensive medication for the minimum washout period. Baseline (Day 0/hour 0) IOP ≥ 22 mm Hg and ≤ 34 mm Hg in each eye (...) and Collaborators Actavis Inc. More Information Go to Layout table for additonal information Responsible Party: Actavis Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: WAT/BNZL/2014 First Posted: July 30, 2015 Last Update Posted: February 2, 2017 Last Verified: February 2017 Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Brinzolamide Carbonic Anhydrase Inhibitors Enzyme

2015 Clinical Trials

80. Stop Retinal Ganglion Cell Dysfunction Study

Hypertension Eye Diseases Timolol Latanoprost Bimatoprost Travoprost Dorzolamide Acetazolamide Brinzolamide Methazolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Anticonvulsants Carbonic Anhydrase Inhibitors Enzyme Inhibitors Diuretics Natriuretic Agents (...) have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%. Drugs could be: Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation. If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure. Drug: Latanoprost

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>